BAN2401 Results Validate Eisai/Biogen's Faith In Alzheimer's Amyloid Tack

 
• By Ian Haydock

In the wake of multiple recent drug failures in the Alzheimer's sector, Eisai and partner Biogen announce "impressive" top-line results for an amyloid-targeting antibody that provide important support for the amyloid hypothesis and may also bode well for the companies' lead candidate in the same class.

magnetic resonance image (MRI) of the brain human
PROMISING ALZHEIMER'S RESULTS FOR EISAI/BIOGEN ANTIBODY • Source: Shutterstock

More from Clinical Trials

More from R&D